Eli Lilly announced it will significantly increase the list prices of its weight-loss drug Mounjaro across European markets, including a 170% hike in the UK. This move aligns with the Trump administration’s push for 'most-favored nation' drug pricing aimed at rebalancing costs globally. The company intends to keep U.S. prices lower by raising prices abroad, a tactic designed to share the financial burden of medical innovation more equitably among developed countries. The price hikes may face scrutiny regarding their impact on European health systems and private payers who often negotiate discounts.